安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CAR 安飞士

休市中 12-20 15:59:59 EST

80.98

+0.04

+0.05%

盘后80.98

+0.000.00%

19:50 EST

最高84.37	最低80.03	成交量141.19万
今开80.51	昨收80.94	日振幅5.36%
总市值28.46亿	流通市值13.71亿	总股本3,514万
成交额1.15亿	换手率8.34%	流通股本1,693万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CAR","market":"US","secType":"STK","nameCN":"安飞士","latestPrice":80.98,"timestamp":1734728399999,"preClose":80.94,"halted":0,"volume":1411925,"hourTrading":{"tag":"盘后","latestPrice":80.98,"preClose":80.98,"latestTime":"19:50 EST","volume":298736,"amount":24191943.655,"timestamp":1734742203805},"delay":0,"floatShares":16927985,"shares":35139198,"eps":11.079278,"marketStatus":"休市中","marketStatusCode":7,"change":0.04,"latestTime":"12-20 15:59:59 EST","open":80.51,"high":84.365,"low":80.0276,"amount":114863925.06675,"amplitude":0.053588,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":11.079278,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"adjPreClose":80.94,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":80.3,"preClose":80.94,"latestTime":"09:19 EST","volume":783,"amount":62749.94886,"timestamp":1734704347520},"postHourTrading":{"tag":"盘后","latestPrice":80.98,"preClose":80.98,"latestTime":"19:50 EST","volume":298736,"amount":24191943.655,"timestamp":1734742203805},"volumeRatio":2.3706444228261554,"impliedVol":0.6326,"impliedVolPercentile":0.5833},"requestUrl":"/m/hq/s/CAR/tweets","defaultTab":"tweets","newsList":[{"id":"2492030115","title":"港股异动 | 永泰生物-B(06978)午后涨超9% CAR-T-19注射液获授予突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2492030115","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492030115?lang=zh_cn&edition=full","pubTime":"2024-12-19 13:48","pubTimestamp":1734587289,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，永泰生物-B午后涨超9%，截至发稿，涨9.65%，报2.5港元，成交额66.03万港元。消息面上，永泰生物近期公布，集团的产品CAR-T–19注射液获得国家药品监督管理局药品审评中心颁发的突破性疗法认定，用于治疗25岁及以下复发╱难治B细胞急性淋巴细胞白血病患者。该认定乃基于CAR-T–19注射液可靠的临床疗效及安全性数据。其将加快CAR-T–19注射液的临床开发，并加速其早日与患者见面。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CAR","BK1161","BK1574","BK4022","BK4230","06978"],"gpt_icon":0},{"id":"2492153409","title":"安飞士盘中异动 下午盘股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492153409","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492153409?lang=zh_cn&edition=full","pubTime":"2024-12-19 03:57","pubTimestamp":1734551838,"startTime":"0","endTime":"0","summary":"北京时间2024年12月19日03时57分，安飞士股票出现异动，股价快速跳水5.06%。截至发稿，该股报84.66美元/股，成交量23.3027万股，换手率0.66%，振幅6.04%。机构评级方面，在所有10家参与评级的机构中，60%的券商给予买入建议，40%的券商给予持有建议，无券商给予卖出建议。安飞士股票所在的租赁服务行业中，整体跌幅为1.75%。公司品牌包括 Avis、Budget 和 Zipcar。Avis 的服务对象为旅游业的高端商业和休闲分部，Budget 则面向重视性价比的客户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121903571895ea59a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121903571895ea59a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAR","BK4230","BK4022"],"gpt_icon":0},{"id":"2492971984","title":"重磅！百亿美元豪赌！吉利德想靠CAR-T再赢一次！","url":"https://stock-news.laohu8.com/highlight/detail?id=2492971984","media":"谈思生物","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492971984?lang=zh_cn&edition=full","pubTime":"2024-12-18 16:23","pubTimestamp":1734510221,"startTime":"0","endTime":"0","summary":"而目前，相比这些更早期的投资，吉利德显然更希望依靠CAR-T疗法再次取得成功。/ 01 /CD19 CAR-T的下坡路2017年，吉利德公司斥资119亿美元收购Kite，这一行动标志着其向肿瘤治疗领域的战略性转型。通过这次收购，吉利德获得了全球仅有的两款获批的CAR-T疗法之一——Yescarta，从而迅速跻身全球细胞与基因治疗领域的领军企业。然而，目前在美国，获批上市的CD19 CAR-T疗法已达5款，在激烈的市场竞争中，吉利德的CAR-T疗法似乎开始面临销售挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218162530a1f80504&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218162530a1f80504&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4550","LU0234570918.USD","IE00B19Z3B42.SGD","BK4139","LU0058720904.USD","IE00BSNM7G36.USD","IE0002270589.USD","BK4585","BK4578","LU1571399168.USD","GILD","LU1839511570.USD","LU2087621335.USD","LU0889565916.HKD","LU0320765992.SGD","IE00B7SZLL34.SGD","LU0109394709.USD","LU1430594728.SGD","BK4532","IE00B3T34201.USD","BK4568","CAR","IE00BKVL7J92.USD","LU1585245621.USD","BK4022","IE00B19Z3581.USD","LU1066053197.SGD","BK4230","BK4566","IE00BZ1G4Q59.USD","LU2468319806.SGD","LU0289739699.SGD","BK4583","LU1066051498.USD","BK4588"],"gpt_icon":0},{"id":"2491634712","title":"吉利德：想靠CAR-T再赢一次","url":"https://stock-news.laohu8.com/highlight/detail?id=2491634712","media":"钛媒体","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491634712?lang=zh_cn&edition=full","pubTime":"2024-12-16 13:59","pubTimestamp":1734328740,"startTime":"0","endTime":"0","summary":"而眼下，相比这些更早期的赌注，吉利德显然更希望靠CAR-T再赢一次。主打安全性亮点的anito-cel，被吉利德寄予厚望，其认为这将是一款BIC产品；加上Kite已经具备的大规模生产能力及CAR-T商业化网络，其认为anito-cel有能力角逐CAR-T这一近千亿市场。CD19 CAR-T的下坡路2017年斥资119亿美元收购Kite，是吉利德转向肿瘤领域的关键举措，这让其获得了全球唯二获批上市的CAR-T疗法Yescarta，更是一跃成为全球细胞与基因治疗的领头羊。可以说，吉利德在CAR-T赛道，风光无两。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216140013ab7b7fe8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216140013ab7b7fe8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GILD","BK4583","IE00B19Z3581.USD","LU0058720904.USD","CAR","LU1839511570.USD","BK4022","IE00BZ1G4Q59.USD","LU1066053197.SGD","LU1430594728.SGD","LU1571399168.USD","IE00BSNM7G36.USD","BK4566","LU2087621335.USD","BK4588","BK4550","LU1066051498.USD","IE00B3T34201.USD","LU2468319806.SGD","LU0109394709.USD","IE0002270589.USD","BK4568","BK4578","BK4532","LU0234570918.USD","LU0320765992.SGD","LU1585245621.USD","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","BK4230","LU0289739699.SGD","BK4585","LU0889565916.HKD"],"gpt_icon":0},{"id":"2490817446","title":"强生(JNJ.US)CAR-T疗法最新研究结果公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2490817446","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490817446?lang=zh_cn&edition=full","pubTime":"2024-12-12 08:03","pubTimestamp":1733961802,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，强生公司日前公布了3期临床试验CARTITUDE-4的最新研究结果。MRD是多发性骨髓瘤患者延长生存期的重要预后指标，MRD阴性意味着采用灵敏检测手段无法检测到血液中存在癌细胞。Cilta-cel是一种针对B细胞成熟抗原的CAR-T细胞免疫疗法，BCMA主要表达于恶性多发性骨髓瘤B细胞和浆细胞的表面。Cilta-cel的嵌合抗原受体蛋白含有两个针对BCMA的接合域，旨在与人类BCMA高亲和力结合。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","IE0002270589.USD","LU1267930813.SGD","LU1718418525.SGD","LU0466842654.USD","IE00B2B36J28.USD","LU1196500208.SGD","JNJ","LU1244550577.SGD","LU0234570918.USD","LU1221951129.SGD","LU2347655156.SGD","BK4532","IE00BSNM7G36.USD","LU1914381329.SGD","IE00BGHQF631.EUR","LU1894683264.USD","LU0320765646.SGD","LU0234572021.USD","LU2089984988.USD","IE00B42XCP33.USD","LU1244550494.USD","CAR","LU1244550221.USD","LU1506573853.SGD","LU2133065610.SGD","LU1732800096.USD","LU0792757196.USD","IE00BVYPNW00.USD","LU1732799900.SGD","LU1066051498.USD","LU1778281490.HKD","BK4588","LU1935042991.SGD","LU0058720904.USD","LU1066051225.USD","IE00B3PB1722.GBP","LU0203345920.USD","IE0009355771.USD","IE0002141913.USD","BK4504","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU1894683348.USD","LU2468319806.SGD","SG9999001440.SGD","LU1674673428.USD","LU0345770308.USD","BK4592","BK4230"],"gpt_icon":0},{"id":"2490483529","title":"永泰生物(06978)CAR-T–19注射液获得国家药监局突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2490483529","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490483529?lang=zh_cn&edition=full","pubTime":"2024-12-11 17:11","pubTimestamp":1733908261,"startTime":"0","endTime":"0","summary":"金吾财讯 | 永泰生物(06978)公布，集团的产品CAR-T–19注射液(一种抗CD19单链抗体嵌合抗原受体T细胞注射液)获得国家药品监督管理局药品审评中心颁发的突破性疗法认定，用于治疗25岁及以下复发╱难治B细胞急性淋巴细胞白血病(“B-ALL”)患者。该认定乃基于CAR-T–19注射液可靠的临床疗效及安全性数据。其将加快CAR-T–19注射液的临床开发，并加速其早日与患者见面。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MTA1YTkyMTYzODE2MDY0MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MTA1YTkyMTYzODE2MDY0MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949453","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR","BK4022","BK1574","BK4230","06978","BK1161"],"gpt_icon":0},{"id":"2490814833","title":"永泰生物-B(06978)：CAR-T-19注射液获授予突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2490814833","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490814833?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:52","pubTimestamp":1733907166,"startTime":"0","endTime":"0","summary":"智通财经APP讯，永泰生物-B 发布公告，集团的产品CAR-T–19注射液获得国家药品监督管理局药品审评中心颁发的突破性疗法认定，用于治疗25岁及以下复发╱难治B细胞急性淋巴细胞白血病患者。该认定乃基于CAR-T–19注射液可靠的临床疗效及安全性数据。其将加快CAR-T–19注射液的临床开发，并加速其早日与患者见面。药品审评中心的突破性疗法认定旨在加快具有显著临床优势的创新药物的临床开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","CAR","06978","BK4230","BK1574","BK4022"],"gpt_icon":0},{"id":"2490879568","title":"港股异动 | 科济药业-B(02171)涨幅扩大至40% 公司在ASH年会上展示多项成果 通用型CAR-T早期数据优异","url":"https://stock-news.laohu8.com/highlight/detail?id=2490879568","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490879568?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:02","pubTimestamp":1733904155,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B尾盘涨幅扩大至40%，截至发稿，涨39.35%，报10.66港元，成交额6.47亿港元。国投证券指出，根据公司2024年ASH年会披露的同种异体CAR-T药物CT0590的早期临床数据，CT0590已显示出可控的安全性，并在多名患者中实现了深度和持久的临床缓解，其未来更多样本量的数据值得静待。此外，目前已有多个研究表明出CAR-T药物在自身免疫疾病显示出临床治愈的潜力，未来公司CAR-T产品在自身免疫疾病领域的应用值得静待。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02171","BK1574","BK4109","LU2463526074.USD","BK1587","BK1161","BK4022","BK4230","BK1585","ASH","CAR"],"gpt_icon":0},{"id":"2490011656","title":"安飞士跌0.21% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2490011656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490011656?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:31","pubTimestamp":1733841064,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时31分，安飞士股票出现异动，股价急速下跌0.21%。截至发稿，该股报100.00美元/股，成交量1.26万股，换手率0.04%，振幅0.00%。安飞士股票所在的租赁服务行业中，整体跌幅为3.73%。其相关个股中，Vestis Corporation、安飞士、Flexshopper, Inc.涨幅较大，Zoomcar Holdings, Inc.、Herc Holdings Inc.、联合租赁较为活跃，换手率分别为0.16%、0.07%、0.06%，振幅较大的相关个股有Herc Holdings Inc.、联合租赁、赫兹租车，振幅分别为3.16%、1.79%、1.29%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223105a1e397a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223105a1e397a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4022","BK4230","CAR"],"gpt_icon":0},{"id":"2490028622","title":"请注意：“特药卡”≠保险产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2490028622","media":"中国金融新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490028622?lang=zh_cn&edition=full","pubTime":"2024-12-10 17:57","pubTimestamp":1733824640,"startTime":"0","endTime":"0","summary":"随着保险销售市场竞争日益激烈，为客户提供种类繁多的各项增值服务成为保险公司拓客、留客的重要方式之一，常见的包括就医绿色通道、预约挂号、在线问诊等。但其中也不乏一些营销人员打着“增值服务”的幌子，给予投保人或被保险人合同以外利益，违反了监管部门的有关规定。近日引发热议的“特药卡”便是如此。《金融时报》...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OuUGvXSXT3BtGHkaBg7dl1WdjB9KZeyiBkdZACWKTBlu0AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OuUGvXSXT3BtGHkaBg7dl1WdjB9KZeyiBkdZACWKTBlu0AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241210A0872100","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241210A0872100","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4022","CAR","BK4230"],"gpt_icon":0},{"id":"2490905610","title":"2024《自然》十大人物：两位中国科学家入选","url":"https://stock-news.laohu8.com/highlight/detail?id=2490905610","media":"Nature Portfolio","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490905610?lang=zh_cn&edition=full","pubTime":"2024-12-10 10:12","pubTimestamp":1733796777,"startTime":"0","endTime":"0","summary":"《自然》年度十大人物每年从全球的重大科学事件中评选出十位人物。《自然》年度十大人物榜单集中了今年的科学里程碑以及其中举足轻重的人物。得知政府未能在2023年预算中提高奖学金金额后，全国46所机构的约1万名研究人员停止工作以示抗议。李春来是决定探测器在月球的着陆点的关键人物，也是首批对返回岩样着手分析的科学家之一。其他两位患有另一种疾病的男性患者表示，他们的症状在几天后开始消失。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8fCDIWEeJUe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK4123","BK4022","BK4547","BK4230","SOS","CAR"],"gpt_icon":0},{"id":"2490793996","title":"港股异动 | 永泰生物-B(06978)早盘涨近20% CAR-T价格仍然制约商业化 公司自制慢病毒载体可降低生产成本","url":"https://stock-news.laohu8.com/highlight/detail?id=2490793996","media":"智通财经网","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490793996?lang=zh_cn&edition=full","pubTime":"2024-12-09 10:35","pubTimestamp":1733711703,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，永泰生物-B早盘涨近20%，截至发稿，涨15.94%，报2.91港元，成交额299.99万港元。消息面上，新版药品目录将于2025年1月1日在全国范围内正式实施，据悉，四款百万元CAR-T细胞疗法并未出现在此次目录名单之列，价格仍然成为商业化的制约因素，原因在于相关原材料的采购仍然依赖进口。通过自制慢病毒载体，能够降低生产成本，加快研发进度，增加产品竞争优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1161","BK4022","BK4230","06978","CAR"],"gpt_icon":0},{"id":"2489201466","title":"国内吸金超30亿美元！MNC押注TCE疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2489201466","media":"动脉vcbeat","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489201466?lang=zh_cn&edition=full","pubTime":"2024-12-08 08:00","pubTimestamp":1733616000,"startTime":"0","endTime":"0","summary":"随着MNC与国内Biotech的BD交易不断涌现，TCE疗法浮出水面，成为医药行业重点押注的赛道。10月31日，艾伯维出手14.65亿美元，押注TCE，与EvolveImmune Therapeutics达成合作，利用其专有的TCE平台共同开发肿瘤药物。10月29日，GSK宣布和恩沐生物达成协议，将以 3 亿美元的预付款收购恩沐生物处于临床阶段的靶向 CD19 和 CD2...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OpuhH2mdQoARizknbFQv1rFhMgqD4OZwlcpBgn31nBhgMAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OpuhH2mdQoARizknbFQv1rFhMgqD4OZwlcpBgn31nBhgMAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241208A01LX800","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241208A01LX800","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["CAR","BK4022","CRS","IE00B66KJ199.SGD","BK4006","BK4230","IE00B19Z4B17.USD","IE0031619046.USD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2489294906","title":"连续四年“陪跑”，百万CAR-T为何刷不上医保？","url":"https://stock-news.laohu8.com/highlight/detail?id=2489294906","media":"动脉vcbeat","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489294906?lang=zh_cn&edition=full","pubTime":"2024-12-07 08:00","pubTimestamp":1733529600,"startTime":"0","endTime":"0","summary":"当下，正值医保结果出炉期，行业里充斥的也大多是“获批”喜讯。比如刚刚单挑“药王”成功的卡度尼利单抗和我国首个获批上市的第三代BCR-ABL抑制剂奥雷巴替尼等多款重磅药，均被纳入此次医保支付范围。据官方数据统计，今年共有91款新药纳入医保，平均降价幅度为63%。但这只是其中一面，相较于前两年目录外药品专家评审通过...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OmkKAL7mOC88RPO1fyduaLV9T7HYsg5ER6LnoLkOlMBvUAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OmkKAL7mOC88RPO1fyduaLV9T7HYsg5ER6LnoLkOlMBvUAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241207A015ZL00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241207A015ZL00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4230","CAR","BK4022"],"gpt_icon":0},{"id":"2489123937","title":"安飞士涨3.37% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2489123937","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489123937?lang=zh_cn&edition=full","pubTime":"2024-12-06 22:32","pubTimestamp":1733495533,"startTime":"0","endTime":"0","summary":"北京时间2024年12月06日22时32分，安飞士股票出现波动，股价大幅上涨3.37%。截至发稿，该股报102.09美元/股，成交量1.4425万股，换手率0.04%，振幅1.64%。最近的财报数据显示，该股实现营业收入34.80亿美元，净利润2.37亿美元，每股收益6.68美元，毛利11.24亿美元，市盈率9.11倍。安飞士股票所在的租赁服务行业中，整体涨幅为1.05%。Avis 的服务对象为旅游业的高端商业和休闲分部，Budget 则面向重视性价比的客户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206223213ab62d4af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206223213ab62d4af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4230","BK4022","CAR"],"gpt_icon":0},{"id":"2489288115","title":"安飞士跌3.27% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2489288115","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489288115?lang=zh_cn&edition=full","pubTime":"2024-12-05 00:01","pubTimestamp":1733328071,"startTime":"0","endTime":"0","summary":"北京时间2024年12月05日00时01分，安飞士股票出现异动，股价快速下跌3.27%。截至发稿，该股报99.53美元/股，成交量4.7635万股，换手率0.14%，振幅3.44%。最近的财报数据显示，该股实现营业收入34.80亿美元，净利润2.37亿美元，每股收益6.68美元，毛利11.24亿美元，市盈率8.92倍。安飞士股票所在的租赁服务行业中，整体跌幅为0.24%。Avis 的服务对象为旅游业的高端商业和休闲分部，Budget 则面向重视性价比的客户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120500011198e56146&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120500011198e56146&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4230","CAR","BK4022"],"gpt_icon":0},{"id":"2488940347","title":"安飞士盘中异动 早盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488940347","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488940347?lang=zh_cn&edition=full","pubTime":"2024-12-04 00:15","pubTimestamp":1733242505,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日00时15分，安飞士股票出现异动，股价快速下挫5.08%。截至发稿，该股报100.55美元/股，成交量8.8926万股，换手率0.25%，振幅5.37%。机构评级方面，在所有10家参与评级的机构中，60%的券商给予买入建议，40%的券商给予持有建议，无券商给予卖出建议。安飞士股票所在的租赁服务行业中，整体跌幅为0.54%。公司品牌包括 Avis、Budget 和 Zipcar。Avis 的服务对象为旅游业的高端商业和休闲分部，Budget 则面向重视性价比的客户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204001506abf32c02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204001506abf32c02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4230","CAR","BK4022"],"gpt_icon":0},{"id":"2486940533","title":"肿瘤创新药物医保新进展：ADC、双抗成功纳入 CAR-T依旧“退场”","url":"https://stock-news.laohu8.com/highlight/detail?id=2486940533","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486940533?lang=zh_cn&edition=full","pubTime":"2024-11-28 18:49","pubTimestamp":1732790959,"startTime":"0","endTime":"0","summary":"每年一度的医保谈判始终是业界翘首以待的盛事。自2018年国家医保局正式成立以来，国家医保局通过将创新药物以公允的价格及时纳入医保目录，以及支持其临床应用的加速等措施，极大地推动了创新药物的发展进程。11月28日，国家医保局详细介绍了2024年国家医保药品目录的调整情况，并正式对外发布了《国家基本医疗保险、工伤保险和生育保险药品目录（2024年版）》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411283253882436.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411283253882436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","BK4022","BK4230","BK1161","ADC","BK1574","BK4080","CAR","06978"],"gpt_icon":0},{"id":"2486353530","title":"国家医保局回应“天价抗癌药”CAR-T为何难进医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486353530","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486353530?lang=zh_cn&edition=full","pubTime":"2024-11-28 12:03","pubTimestamp":1732766603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","BK1574","159992","06978","CAR","BK4230","BK4022"],"gpt_icon":0},{"id":"2486584543","title":"港股异动 | 科济药业-B(02171)现跌近7% CAR-T细胞疗法未进入新版医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486584543","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486584543?lang=zh_cn&edition=full","pubTime":"2024-11-28 11:52","pubTimestamp":1732765937,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B(02171)现跌近7%，截至发稿，跌5.95%，报6.95港元，成交额5429.62万港元。消息面上，据财联社报道，记者根据今日发布的2024年国家医保目录发现，包括科济药业的泽沃基奥仑赛注射液在内的四款百万元CAR-T细胞疗法并未出现在目录名单之列。值得注意的是，科济药业11月6日在公司官微上公布了其产品赛恺泽（泽沃基奥仑赛注射液）、CT071和CT0590的数据，并宣布这三项数据将在第66届美国血液学会（ASH）年会上以壁报形式展示，该会议将于12月7日至10日举行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4022","BK4230","BK1587","BK1585","BK1161","BK1574","02171","CAR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avisbudgetgroup.com","stockEarnings":[{"period":"1week","weight":-0.1216},{"period":"1month","weight":-0.1825},{"period":"3month","weight":-0.0573},{"period":"6month","weight":-0.2794},{"period":"1year","weight":-0.5617},{"period":"ytd","weight":-0.5432}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avis Budget Group, Inc.是一家在特拉华州成立，总部位于新泽西州帕西帕尼市的公司。艾维士·巴吉集团为全球企业和消费者提供汽车和卡车租赁和配套服务。该公司经营着两家全球汽车租赁行业中最知名的品牌Avis和Budget。 Avis是一家领先的汽车租赁供应商，定位于服务旅游业的优质商业和休闲领域，而Budget是一家领先的汽车租赁供应商，业务主要集在该行业中更具价值意识的部分。该公司是领先的汽车租赁运营商，在北美，澳大利亚，新西兰和其他地区都有业务服务，该公司授权在世界各地以Avis和Budget品牌经营的国家就有超过180个多个。该公司通常在机场汽车租赁收入中占有主要份额，并运营着美国主要的卡车租赁业务之一。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.012765},{"month":2,"riseRate":0.642857,"avgChangeRate":0.055699},{"month":3,"riseRate":0.642857,"avgChangeRate":0.042142},{"month":4,"riseRate":0.642857,"avgChangeRate":0.012091},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.006618},{"month":6,"riseRate":0.5,"avgChangeRate":0.008098},{"month":7,"riseRate":0.571429,"avgChangeRate":0.042418},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.005429},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.030283},{"month":10,"riseRate":0.714286,"avgChangeRate":0.13912},{"month":11,"riseRate":0.714286,"avgChangeRate":0.082032},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.04668}],"exchange":"NASDAQ","name":"安飞士","nameEN":"Avis Budget"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安飞士,CAR,安飞士股票,安飞士股票老虎,安飞士股票老虎国际,安飞士行情,安飞士股票行情,安飞士股价,安飞士股市,安飞士股票价格,安飞士股票交易,安飞士股票购买,安飞士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}